Cowen assumed coverage on shares of Surface Oncology (NASDAQ:SURF) in a research report sent to investors on Monday morning, Marketbeat Ratings reports. The brokerage issued an outperform rating on the stock.
Separately, Evercore ISI began coverage on Surface Oncology in a research note on Monday. They issued an outperform rating and a $26.00 target price for the company.
Shares of SURF opened at $13.99 on Monday. Surface Oncology has a 52-week low of $13.75 and a 52-week high of $13.75.
In related news, Director David S. Grayzel bought 100,000 shares of the business’s stock in a transaction on Monday, April 23rd. The stock was acquired at an average cost of $15.00 per share, with a total value of $1,500,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Lilly Ventures Fund I. Llc bought 266,000 shares of the business’s stock in a transaction on Monday, April 23rd. The stock was bought at an average cost of $15.00 per share, with a total value of $3,990,000.00. The disclosure for this purchase can be found here.
Surface Oncology Company Profile
Surface Oncology, Inc, a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company's lead product candidate is the SRF231 that is in Phase I clinical trial targeting protein called cluster of differentiation (CD) 47. It is also developing SRF373 inhibiting CD73; SRF617 inhibiting CD39; and SRF388, an antibody targeting interleukin 27.
Receive News & Ratings for Surface Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surface Oncology and related companies with MarketBeat.com's FREE daily email newsletter.